Abiraterone, a CYP17 inhibitor, elevates steroidal compound levels, leading to secondary mineralocorticoid excess, possibly explaining its higher HF risk compared with enzalutamide, a drug with similar indications.16 Screening and follow-up for ADT-treated prostate cancer patients may be difficult, but focus should be placed on high-risk groups (history of HF, hypertension, atrial fibrillation, or use of ADT medications with hypermineralocorticoid properties). This evidence concerns the gene CYP17A1 and Familial prostate cancer.